Main Article Content
Pancreatic cancer is a disease with high mortality. It is predicted to become the second leading cause of cancer death in some regions of the world. Frequent diagnosis at an advanced stage contributes to 5-year survival at a highly unsatisfactory level of 2–9%. Due to the lack of early symptoms, nearly 80% of patients receive a diagnosis when distant metastases develop. So far, the most frequently used programs in the treatment of patients with pancreatic cancer in the stage of neoplastic spreading include: FOLFIRINOX (oxaliplatin, 5-fluorouracil, irinotecan, leucovorin), gemcitabine alone or in combination with nab-paclitaxel or erlotinib.
Based on the results of the phase III study NAPOLI-1, liposomal irinotecan in combination with 5-fluorouracil (5-FU) and leucovorin (LV ) was approved as the first regimen for use in the second or subsequent line of therapy in patients with advanced pancreatic cancer previously treated with gemcitabine. This paper presents a case of a patient with advanced pancreatic cancer who was treated with two lines of chemotherapy – gemcitabine in combination with nab-paclitaxel and liposomal irinotecan with 5-FU/LV . The treatment was well tolerated and was considered a valuable therapeutic option. A 2-year overall survival was obtained from the diagnosis of the disease.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (firstname.lastname@example.org)
2. Lambert A, Schwarz L, Borbath I et al. An update on treatment options for pancreatic adenocarcinoma. Adv Med Oncol. 2019; 11: 1143.
3. McGuigan A, Kelly P, Turkington RC et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846-61.
4. Taieb J, Abdallah R. How I treat pancreatic cancer. ESMO Open. 2020; 4: e000818. https://doi.org/10.1136/.Esmo open-2020-0008.
5. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-6.
6. Jassem J, Krzakowski M, Potemski P. Nowotwory układu pokarmowego. 2nd ed. Via Medica, Gdańsk 2019.
7. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011; 364: 1817-25.
8. Tempero MA, Malafa MP, Chiorean EG et al. Pancreatic adenocarcinoma, version 1.2021. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(3): 202-10.
9. Tehfe M, Dowden S, Kennecke H et al. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Adv Ther. 2016; 33(5): 747-59.
10. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-703.
11. Czyżykowski R, Janiak M, Krakowska M et al. Palliative systemic treatment of patients with pancreatic cancer – should reimbursement of nab-paclitaxel change the current management paradigm? Oncol Clin Pract. 2017; 13: 8-13.
12. Wang-Gillam A, Li C-P, Bodoky G et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016; 387: 545-57.
13. Klank-Sokołowska E, Kucharewicz M, Wojtukiewicz MZ. Nanoliposomalny irynotekan – nowe perspektywy leczenia uogólnionego raka trzustki. Onkol Prakt Klin. 2019; 5: 1-9.